Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20668053 | 0.86 | ALDH1A1 (0.56) | HTR1AHTR7ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL24488893 | 0.80 | HTR1A (0.60) | HTR1AHTR7ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL29990964 | 0.79 | KDM4E (0.43) | HTR1AHTR7ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL5435622 | 0.78 | KDM4E (0.60) | HTR1AHTR7ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL20659873 | 0.77 | SMN1; SMN2 (0.56) | HTR1AHTR7ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL24490579 | 0.76 | HTR1A (0.41) | HTR1AHTR7ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL23723689 | 0.75 | RAB9A (0.59) | ALDH1A1SMN1; SMN2HTTKDM4EPDE5A | |
| SCHEMBL28637506 | 0.73 | KDM4E (0.41) | HTR1AHTR7ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL18701573 | 0.73 | KDM4E (0.41) | HTR1AHTR7ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL18711843 | 0.73 | KDM4E (0.41) | HTR1AHTR7ALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240154124-A1 | NEGATIVE ELECTRODE PLATE AND LITHIUM-ION BATTERY COMPRISING SAME | ZHUHAI COSMX BATTERY CO., LTD. (CN) | 2024-05-09 | — | — | US | claimed |
| US-20240154124-A1 | NEGATIVE ELECTRODE PLATE AND LITHIUM-ION BATTERY COMPRISING SAME | ZHUHAI COSMX BATTERY CO., LTD. (CN) | 2024-05-09 | — | — | US | disclosed |
| CN-110590806-B | Chalcone analogue containing thieno [2,3-d ] pyrimidine-2-yl and preparation method and application thereof | 深圳大学 | 2021-10-29 | — | — | CN | disclosed |
| CN-110590806-A | Chalcone analogue containing thieno [2,3-d ] pyrimidine-2-yl and preparation method and application thereof | 深圳大学 | 2019-12-20 | — | — | CN | disclosed |
| US-RE46942-E1 | 4-piperidinyl compounds for use as tankyrase inhibitors | NOVARTIS AG (CH) | 2018-07-10 | — | — | US | disclosed |
| US-9163003-B2 | 4-piperidinyl compounds for use as tankyrase inhibitors | NOVARTIS AG (CH) | 2015-10-20 | — | — | US | disclosed |
| EP-2731940-B1 | 4 - PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-20150126513-A1 | 4-PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| EP-2731940-A1 | 4 - PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | Novartis AG (CH) | 2014-05-21 | — | — | EP | disclosed |
| EP-2209791-B1 | Heterocyclic derivatives | MERCK SHARP & DOHME (NL) | 2014-01-22 | — | — | EP | disclosed |
| EP-2209791-B1 | Heterocyclic derivatives | MERCK SHARP & DOHME (NL) | 2014-01-22 | — | — | EP | disclosed |
| WO-2013008217-A1 | 4 - PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| US-8129397-B2 | Substituted thieno[2,3-d]pyrimidines as AMPA modulators | MSD OSS B.V. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129397-B2 | Substituted thieno[2,3-d]pyrimidines as AMPA modulators | MSD OSS B.V. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129397-B2 | Substituted thieno[2,3-d]pyrimidines as AMPA modulators | MSD OSS B.V. (US) | 2012-03-06 | — | — | US | disclosed |
| WO-2009062930-A1 | HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131455-A1 | HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2009-05-21 | — | — | US | disclosed |
| US-20090131455-A1 | HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2009-05-21 | — | — | US | disclosed |
| US-20090131455-A1 | HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126513-A1 | 4-PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | TNKS1BP1, WNT1, TNKS | HTR1A 2227/4885HTR7 3376/4885ALDH1A1 1013/4885 |
| US-20090131455-A1 | HETEROCYCLIC DERIVATIVES | GRIN2C, GRIK5, GRIN1 | HTR1A 135/4885HTR7 124/4885ALDH1A1 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.